Manager of Division of Transfusion Medicine and Hemophilia Treatment CenterHiroshima University HospitalHiroshima, Hiroshima, Japan
PB0535 - How much is the coagulation ability of emicizumab in hemophilia A patients treated with it, when converted to factor VIII activity?
Monday, June 24, 202413:45 – 14:45 ICT
OC 50.4 - Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in hemophilia A with inhibitor (UNEBI Study): Multicenter open-label non-randomized trial.
Tuesday, June 25, 202410:15 – 10:30 ICT
.jpeg.jpg "Teruhisa Fujii photo")